Raymond Osarogiagbon, MD, discusses the challenges of implementing lung cancer screening guidelines and the need for increased awareness and access.

At this year’s American Association for Cancer Research (AACR) Annual Meeting in Chicago, the German drugmaker added durability and progression free survival (PFS) results to the breadth of data ...

Despite new paradigm-shifting treatments, lung cancer remains a deadly disease – and improving outcomes requires more than just drug research. The new Lung Ambition Alliance – launched in July ...

The investigational oral tyrosine kinase inhibitor (TKI) zongertinib showed promise in patients with previously treated HER2-mutant non-small cell lung cancer (NSCLC) in a multicohort phase Ia/Ib ...

NERLYNX is designed to block human epidermal growth factor receptor 2 (HER2) in order to treat and limit breast cancer metastasis. Under the agreement, Er-Kim is appointed as the distribution ... the ...

AstraZeneca’s hopes of positioning its PD-L1 inhibitor Imfinzi as a post-surgery therapy for people with earlier-stage lung cancer have taken a knock, although it performed well in a bladder ...

As a highlight of Lesbian Visibility Week, the Curve Power List celebrates LGBTQ+ women and nonbinary individuals making ...

Next week, the American Lung Association in Ohio kicks off Lung Cancer Action Week in Cleveland to raise awareness of lung cancer and encourage residents to take action to end the disease. The annual ...

In short, the study highlights a potential new path forward for treating small-cell lung cancer using Supinoxin—a drug that targets the cancer cells’ energy production systems through RNA biology.